NEWARK, Calif., Nov. 13, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at two upcoming healthcare investor conferences in New York.
Event: Stifel 2019 Healthcare Conference
Date: Wednesday, Nov. 20
Time: 2:25 p.m. EST
Event: Piper Jaffray 31st Annual Healthcare Conference
Date: Thursday, Dec. 5
Time: 1:30 p.m. EST
Live and archived audio webcasts of the Stifel and Piper presentations can be accessed by visiting the Investors page of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-300 is an injectable hepcidin mimetic in development for the potential treatment of iron overload anemia and related rare blood diseases including beta-thalassemia and polycythemia vera. PTG-200 is an oral, gut-restricted interleukin-23 receptor specific antagonist peptide in Phase 2 clinical development for the potential treatment of inflammatory bowel disease, with Crohn's disease as the initial indication. The Company has a worldwide license and collaboration agreement with Janssen Biotech for the clinical development of PTG-200. PN-943 is an oral, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in clinical development for the potential treatment of inflammatory bowel disease, with a Phase 2 ulcerative colitis study expected to commence in the first half of 2020.
Protagonist is headquartered in Newark, California. For further information, please visit http://www.protagonist-inc.com.
View original content:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-two-upcoming-healthcare-investor-conferences-300957130.html
SOURCE Protagonist Therapeutics, Inc.
Solebury Trout, Rich Allan (media), Tel: +1 646-378-2958, Email: email@example.com, OR Brian Korb (investors), Tel: +1 646-378-2923, Email: firstname.lastname@example.org